文献速递药物相互作用药物不良反应与药物警戒

沙库巴曲/缬沙坦与西地那非在轻中度高血压患者中的药代与药效药物相互作用评价

Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension.
PubMed 文献 · Clin Pharmacol Ther · 2017-11-03

本研究在轻中度高血压患者中评估沙库巴曲/缬沙坦与西地那非的药代与药效相互作用。开放标签、三周期、单序列设计,患者依次接受单剂西地那非50mg、沙库巴曲/缬沙坦400mg每日一次共5天、以及两者合用。合用后缬沙坦AUC和Cmax分别下降29%和39%,且血压降幅大于单用沙库巴曲/缬沙坦,提示合用需谨慎。

要点

  • 合用西地那非使缬沙坦AUC下降29%、Cmax下降39%。
  • 合用后动态血压降幅大于单用沙库巴曲/缬沙坦。
  • 接受沙库巴曲/缬沙坦者应谨慎使用西地那非。

核心结论

  • 沙库巴曲/缬沙坦与西地那非合用会降低缬沙坦暴露并增强降压效应,临床应谨慎合用。

研究设计与样本

  • 开放标签、三周期、单序列研究,纳入轻中度高血压患者,平均收缩压153.8±8.2 mmHg。
  • 患者依次接受单剂西地那非50 mg、沙库巴曲/缬沙坦400 mg每日一次共5天、以及两者合用。

主要发现

  • 合用西地那非时缬沙坦AUC下降29%、Cmax下降39%。
  • 合用沙库巴曲/缬沙坦与西地那非后动态收缩压/舒张压/平均动脉压较单用沙库巴曲/缬沙坦额外降低-5/-4/-4 mmHg。
  • 两种治疗在本研究中总体安全且耐受良好。

关键数值与推荐

  • 缬沙坦AUC下降29%、Cmax下降39%(与西地那非合用时)。
  • 额外血压降幅为动态收缩压/舒张压/平均动脉压-5/-4/-4 mmHg(合用较单用沙库巴曲/缬沙坦)。

临床怎么用

  • 对接受沙库巴曲/缬沙坦的患者处方西地那非时应谨慎,并关注血压变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sacubitril/valsartan (LCZ696) is indicated for the treatment of patients with heart failure and reduced ejection fraction (HFrEF). Since patients with HFrEF may receive sacubitril/valsartan and sildenafil, both increasing cyclic guanosine monophosphate, the present study evaluated the pharmacokinetic and pharmacodynamic drug interaction potential between sacubitril/valsartan and sildenafil. In this open-label, three-period, single sequence study, patients with mild-to-moderate hypertension (153.8 ± 8.2 mmHg mean systolic blood pressure (SBP)) received a single dose of sildenafil 50 mg, sacubitril/valsartan 400 mg once daily for 5 days, and sacubitril/valsartan and sildenafil coadministration. When coadministered with sildenafil, the AUC and Cmax of valsartan decreased by 29% and 39%, respectively. Coadministration of sacubitril/valsartan and sildenafil resulted in a greater decrease in BP (-5/-4/-4 mmHg mean ambulatory SBP/DBP/MAP (mean arterial pressure)) than with sacubitril/valsartan alone. Both treatments were generally safe and well tolerated in this study; however, the additional BP reduction suggests that sildenafil should be administered cautiously in patients receiving sacubitril/valsartan. Unique identifier: NCT01601470.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hsiao HL, Langenickel TH, Petruck J, et al. Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension. Clin Pharmacol Ther. 2017. PMID: 28599060. doi:10.1002/cpt.759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。